Last updated: February 15, 2026
Overview
NDC 45802-0706 corresponds to a proprietary formulation of carboplatin, a platinum-based chemotherapy agent indicated primarily for ovarian, lung, and other solid tumors. The drug’s primary competitors include cisplatin, cisplatin formulations, and newer platinum compounds. The market landscape is influenced by oncology treatment trends, reimbursement policies, drug supplier dynamics, and patent expirations.
Market Size and Demand Drivers
-
Indications & Usage: Carboplatin is indicated for ovarian carcinoma, small cell lung cancer, and other solid tumors. The prevalence of these conditions drives demand; ovarian cancer affects approximately 22,000 women annually in the U.S. (source: SEER data[1]), with carboplatin used as first-line therapy in many cases.
-
Market Penetration: Utility in combination regimens (e.g., with paclitaxel) sustains high utilization. The shift toward targeted therapies and immunotherapies has not substantially replaced platinum agents but may influence adjunct use.
-
Geographic Scope: The U.S. represents roughly 50-60% of global chemotherapy sales. Emerging markets show increasing adoption, driven by expanding healthcare infrastructure.
Competitive Landscape
| Competitor Drugs |
Indications |
Patents & Exclusivity |
Market Share (Estimated) |
| Cisplatin (and generics) |
Broad indication; established drug |
Patent expired; generics available |
40-50% |
| Liposomal Cisplatin |
Ovarian and lung cancers |
Patent life ended; limited market penetration |
10-15% |
| Carboplatin (including NDC 45802-0706) |
Ovarian, lung, others |
Patent until approximately 2024, with biosimilar entry |
25-30% |
| Newer platinum agents |
Experimental or limited indications |
Under patent; newer agents in clinical trials |
5-10% |
Pricing Trends and Projections
-
Current Pricing: The average wholesale price (AWP) for a 50 mg vial of carboplatin (including proprietary formulations) ranges from USD 50-70. The price encodes for volume discounts, payer negotiations, and regional variation.
-
Historical Trends: Over the past five years, prices have decreased modestly, attributable to increased generic competition. For branded formulations, prices have stabilized around USD 80-100 per vial in certain markets.
-
Impact of Patent Expiration: With patents expiring circa 2024, generic and biosimilar versions are expected to enter the market, exerting downward pressure on prices.
Price Projection (Next 3-5 Years)
| Year |
Estimated Price Range (USD per vial) |
Key Factors |
| 2023 |
USD 80-100 |
Patent exclusivity; limited generic options |
| 2024 |
USD 50-70 |
Entry of biosimilars and generics |
| 2025-2028 |
USD 45-65 |
Increased market competition; price erosion stabilizes |
| 2028+ |
USD 40-55 |
Further generic proliferation, healthcare cost containment |
Market Risks & Opportunities
- Risks: Patent expiration leading to price erosion, emergence of alternative therapies, regulatory hurdles for biosimilar approval, supply chain disruptions.
- Opportunities: New formulations with improved safety profiles, combination product opportunities, expanding use in emerging markets.
Regulatory and Reimbursement Environment
- The U.S. FDA classifies carboplatin as an established, generic oncology drug. Pricing depends heavily on payer negotiations, hospital formulary decisions, and insurance reimbursement policies.
- Reimbursement rates tend to favor lower-cost generic options. The inclusion of biosimilars is likely to further pressure prices downward.
Key Takeaways
- NDC 45802-0706 is a proprietary formulation of carboplatin with stable market share due to established indications.
- The market is highly competitive, with generics and biosimilars poised to dominate once patent exclusivity ends.
- Prices are expected to decline from approximately USD 80-100 per vial in 2023 to USD 40-55 by 2028, with continued downward pressure from increased competition.
- Demand remains steady in ovarian and lung cancers, but shifts toward targeted and immune therapies could impact future growth.
- Market expansion into emerging economies offers growth but faces regulatory and reimbursement challenges.
FAQs
1. How does the patent status affect pricing for NDC 45802-0706?
Patent exclusivity delays generic competition, allowing higher pricing. Once patents expire (anticipated 2024), biosimilar and generic versions will lower prices significantly.
2. What are the primary competitors to this formulation?
Generic cisplatin, liposomal cisplatin, and emerging platinum agents are primary competitors. The competition mainly affects market share and pricing.
3. What external factors could influence future demand?
Advancements in targeted and immunotherapy could reduce reliance on platinum-based agents, but current clinical practice still demands carboplatin for many indications.
4. How will biosimilar entry impact market dynamics?
Biosimilars will likely reduce prices, increase access, and shift market share away from branded formulations.
5. What regional factors impact pricing and adoption?
Increased healthcare infrastructure and regulatory approval processes in emerging markets can boost demand but face pricing and reimbursement barriers.
Citations:
[1] SEER Cancer Stat Facts: Ovarian Cancer. National Cancer Institute.
